（来源：廊坊日报） 下一步，廊坊开发区将深化与雄安新区的协同联动，加快推动入选场景落地见效，持续强化科技创新与 项目支撑，不断提升医疗健康服务数字化、智能化水平，全力推动生命健康产业高质量发展。 此次入选的健康大数据应用场景精准对接行业发展痛点，技术领先、实用性强。其中，智能体检软件应 用场景，聚焦流程繁琐、数据割裂、人工质控等问题，运用物联网、大数据、人工智能技术，打造一站 式智能体检管理平台，实现智能导检、无纸化运行和阳性结果智能预警，有效提升服务效率与诊疗精准 度。老年人体检全流程智能服务场景，针对老年人体检不便、报告难懂、数据利用率低等实际问题，搭 建智慧公卫服务平台，通过智能预约、智能解读、个性化干预、数据闭环管理，推动公共卫生服务向精 准化、智能化升级。 华科全维OCT智能制造与研发中心建设场景，聚焦高端医疗影像设备国产化短板，整合人工智能算法、 神经网络与智能生产系统，建设集研发、实验室、洁净生产于一体的现代化基地，构建全链条创新制造 体系，助力突破关键技术瓶颈，提升自主可控能力。 近年来，廊坊开发区立足京津冀协同发展区位优势，将生命健康产业作为重点培育产业，持续优化产业 生态。依托中国医学科学 ...

智慧健康科技此前发布公告，伴随全球人口结构变化与健康意识提升，大健康产业正迎来前所未有的发 展机遇。特别是在中国，随着老龄化进程加快及数字技术广泛应用，以"银发经济"为代表的大健康市场 持续扩大。为积极响应国家"健康中国"战略导向，在稳固所有现有业务的前提下，集团在既有健康相关 业务的基础上，重点发力大健康、数字医疗与康养服务，构建"预防-诊疗-用药-康复-护理"全周期健康 服务生态，以期该板块业务为集团收入做出更大贡献。 香港联交所最新资料显示，2月23日，智慧健康科技(01715)股东将股票由华通证券转入方德证券，转仓 市值829.03万港元，占比5.16%。 ...

Core Viewpoint - The announcement from Health Road (02587) marks a significant transition from a strategic investment phase to a value harvesting phase, with projected revenue of at least RMB 1.5 billion for the fiscal year 2025, representing over 25% year-on-year growth, and a net profit of at least RMB 50 million, indicating a historic turnaround [1] Group 1: Revenue and Profit Growth - The company expects its information technology services revenue to rise from RMB 296 million in 2024 to at least RMB 350 million in 2025, driven by the launch of big data technology services and AI products [1] - Health Road's AI software products are projected to contribute approximately RMB 30 million in scaled revenue by 2025, marking the transition of its AI strategy from concept validation to commercialization [1] Group 2: AI and Operational Efficiency - Health Road has developed a "digital employee" model that effectively addresses efficiency pain points in the healthcare industry, allowing for significant operational cost reductions [2] - The AI assistant for doctors reduces administrative burdens, while the AI health manager provides low-cost chronic disease management and reminders for patients, enhancing operational efficiency [2] Group 3: Market Opportunities - The shift of pharmaceutical companies' marketing budgets towards digital channels opens up a market potential estimated between RMB 800 billion to 1 trillion, as traditional marketing models face systemic upgrades [2] - Health Road's extensive network, connecting over 12,000 hospitals and more than 900,000 registered doctors, positions it as a natural platform for capturing this budget transition [3] Group 4: Content Services and Growth Drivers - The company's content services revenue is expected to surge from RMB 577 million in 2024 to at least RMB 800 million in 2025, becoming a core driver of sustained revenue and profit growth [3] - The implementation of tiered diagnosis and treatment policies and the push for digital health services in county-level medical institutions create a solid foundation for long-term growth [3] Group 5: Strategic Positioning and Future Outlook - Health Road is positioned as a foundational infrastructure in the digital healthcare sector, with a unique dual-end model that enhances its market valuation potential [4] - The anticipated profit turnaround in 2025 is seen as the beginning of value release, with AI technology expected to penetrate more specialized disease management areas and county-level scenarios [4]

智通财经APP获悉，香港联交所最新资料显示，2月23日，智慧健康科技(01715)股东将股票由华通证券 转入方德证券，转仓市值829.03万港元，占比5.16%。 智慧健康科技此前发布公告，伴随全球人口结构变化与健康意识提升，大健康产业正迎来前所未有的发 展机遇。特别是在中国，随着老龄化进程加快及数字技术广泛应用，以"银发经济"为代表的大健康市场 持续扩大。为积极响应国家"健康中国"战略导向，在稳固所有现有业务的前提下，集团在既有健康相关 业务的基础上，重点发力大健康、数字医疗与康养服务，构建"预防-诊疗-用药-康复-护理"全周期健康 服务生态，以期该板块业务为集团收入做出更大贡献。 ...

智通财经APP了解到，在数字医疗行业普遍面临"AI落地难、变现难"的困境之时，健康之路自主研发的 AI软件产品在2025年即贡献约3000万元规模化收入，标志着健康之路的AI战略已从概念验证阶段正式 迈入商业化阶段。 得益于大数据技术服务及AI产品的推出，健康之路信息技术服务板块收入预计从2024年的2.96亿元攀升 至2025年的不少于3.5亿元。据智通财经APP了解，健康之路AI业务之所以能迅速获得市场认可，核心 则在于其独特的"数字员工"模式精准击中了医疗行业的效率痛点。 2月12日，健康之路（02587）发布的一则盈喜公告，犹如一道分水岭，清晰地划定了健康之路从战略投 入期向价值收获期的跨越。 根据公告，公司预期2025财年录得收入不少于人民币15亿元，同比增长超25%，净利润更是实现不少于 人民币5000万元的历史性反转。若深入剖析这则盈喜公告，最令人瞩目的并非单纯的利润数字，而是其 背后高质量的收入结构变化，尤其是AI盈利能力的商业化验证。 不同于通用大模型的"军备竞赛"，健康之路选择了一条更为务实的垂直应用路径，即通过对沉淀二十余 年的海量医患交互数据进行深度学习，健康之路构建了具备"高智商、高 ...

Core Insights - The health industry is experiencing unprecedented growth opportunities due to factors such as an aging global population, the prevalence of chronic diseases, rising consumer awareness, and innovations in artificial intelligence (AI) and digital technology [1][2] - In China, the aging process and widespread application of digital technology are expanding the "silver economy" within the health market [1] - The company aims to develop health, digital medical, and wellness services in response to the national "Healthy China" strategy, focusing on a three-dimensional health service ecosystem that transitions health management from "disease treatment" to "prevention and maintenance" [1] Group 1 - The company has recently completed the acquisition of Zhongshan Yuanqi Smart Health Technology Co., Ltd. and formed a research and development team composed of professionals in data science and health management [1] - This team will focus on health data analysis and intelligent services, developing a one-stop health management platform for real-time monitoring of health data across all demographics and life stages [1] - The platform will leverage general artificial intelligence (AGI) technology to promote healthy lifestyles and concepts to users [1] Group 2 - The platform is planned to integrate dynamic vital sign monitoring, intelligent risk assessment, personalized health interventions, and medication reminders, with connections to medical institutions, wellness service providers, and home care scenarios [2] - The company plans to increase investment in general artificial intelligence and big data systems in the health sector over the next three years to continuously advance technology iteration and platform optimization [2] - Once operational, the platform is expected to significantly enhance the company's revenue annually and gradually establish a dual-driven profit model through technology output and service subscriptions [2]

Core Viewpoint - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series, with Health 160 (02656) being included in the Hang Seng Composite Index, effective March 9, 2026 [1] Group 1: Company Overview - Health 160 is an experienced Chinese pharmaceutical and health products wholesaler and a leading provider of integrated digital healthcare services [1] - The company offers a variety of pharmaceutical health products and comprehensive digital healthcare solutions [1] - Health 160 operates an online healthcare service platform that connects various participants in the healthcare industry [1] Group 2: Market Impact - The inclusion of Health 160 in the Hang Seng Composite Index may lead to its potential addition to the Stock Connect program, as it meets criteria such as market capitalization, liquidity, and listing duration [1] - As of March 31, 2025, Health 160's platform has connected over 44,600 healthcare institutions since its establishment [1]

Core Viewpoint - The health industry is experiencing unprecedented growth opportunities driven by factors such as an aging population, prevalence of chronic diseases, rising consumer awareness, and innovations in artificial intelligence (AI) and digital technology [1][2] Group 1: Market Trends - The aging process in China and the widespread application of digital technology are expanding the "silver economy" within the health market [1] - The company aims to align with the national "Healthy China" strategy by developing health, digital medical, and wellness services [1] Group 2: Business Strategy - The company is focusing on building a three-dimensional health service ecosystem based on AI technology, which includes "smart health devices + community health services + digital empowerment" [1] - The company has recently completed the acquisition of Zhongshan Yuanqi Smart Health Technology Co., Ltd. and formed a research and development team with expertise in data science and health management [1] Group 3: Platform Development - The planned health management platform will integrate dynamic vital sign monitoring, intelligent risk assessment, personalized health interventions, and medication reminders, with connections to medical institutions and home care scenarios [2] - The company plans to increase investment in general AI and big data systems in the health sector over the next three years to enhance technology iteration and platform optimization [2] Group 4: Financial Outlook - The platform is expected to significantly boost the company's revenue once operational, creating a dual-driven profit model through technology output and service subscriptions [2] - The company believes that developing health, digital medical, and wellness services will enrich its existing business structure and cultivate new profit growth points, ultimately creating long-term sustainable value for shareholders and investors [2]

Core Viewpoint - The health industry is experiencing unprecedented growth opportunities driven by factors such as an aging global population, the prevalence of chronic diseases, rising consumer awareness, and innovations in artificial intelligence (AI) and digital technology [1] Group 1: Industry Trends - The aging population and widespread application of digital technology in China are expanding the "silver economy" within the health market [1] - The company aims to align with the national "Healthy China" strategy by developing health, digital medical, and wellness services [1] Group 2: Company Initiatives - The company has completed the acquisition of Zhongshan Yuanqi Smart Health Technology Co., Ltd. and formed a research team of professionals in data science and health management [1] - The research team will focus on health data analysis and intelligent services, developing a one-stop health management platform for real-time monitoring of health data across all demographics and life stages [1] Group 3: Platform Development - The planned platform will integrate dynamic vital sign monitoring, intelligent risk assessment, personalized health interventions, and medication reminders, with connections to medical institutions and home care services [2] - The company plans to increase investment in general AI and big data systems in the health sector over the next three years, expecting significant revenue growth once the platform is operational [2]

招股书显示，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。此外，该公司亦通过在线医疗健康 服务平台-健康160平台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方。截至 2025年3月31日，健康160的平台自成立以来已累计连接超过44,600家医疗健康机构。 智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果， 其中健康160(02656)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9 日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，健康160有可能 被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。 ...